Abstract
For the last few decades, fungal pathogens have been reported to cause different types of human diseases, especially among patients who are immunocompromised. These fungal species are normally present in the mouth and gastrointestinal tracts of healthy individuals, but behave as a potential opportunistic pathogen in immunocompromised patients. Most antifungal pharmaceutical drugs such as amphotericin B, voriconazole, and itraconazole, apart from inhibiting fungal growth and development, also cause serious side effects in the host. Therefore, there is an essential need to develop novel antifungal drugs that can be more reliable with minimal or no side effects. High-resolution mass spectrometry-based proteomics is a potent tool for quantitative profiling of proteins. It has resulted in advanced research in the area of fungal biology, thereby showing promise in the development of novel antifungal drugs. Proteomics studies of host-fungal interactions have resulted in the development of new therapeutic approaches to treat patients suffering from fungal infections worldwide.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: New and Future Developments in Microbial Biotechnology and Bioengineering
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
